INTERNATIONAL JOURNAL OF
PHARMACEUTICAL AND HEALTHCARE INNOVATION
journal homepage: www.ijphi.com

OPEN ACCESS

Review Article

Car-T cells therapy: A revolutionary approach for malignancy

Ali Athar[1], Md Kaif Siddique[1], Atharva Jaiswal[1], Ahsan Ahmed Khan[1], Aditya Singh*[1], Shubhrat Maheshwari[2] Abhishek Kuma[3]

[1]Department of Pharmacy, Faculty of Pharmacy, Integral University Lucknow-226026, India
[2]Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj Uttar Pradesh 211007, India
[3]Institute of Pharmacy, Shri Ramswaroop Memorial University, Lucknow Dewa Road, Uttar Pradesh, India,225003

Article Info

Article history:

Manuscript ID:
162428202025
Received: 16-October -2024
Revised :24- December -2024
Accepted: 28- January 2025
Available online: January 2025

Keywords:
Chimeric antigen receptor, Human leucocyte antigen, Cytokine release syndrome, T cells receptor.

Corresponding Author:
simmu5adityasingh@gmail.com

Abstract

Chimeric antigen receptor (CAR)-T cells therapy functions as adoptive cell therapy. Transferred cancer cells (CAR-T cells) therapy works by retraining a patient's T cells toward their natural tumor-fighting abilities. Scientists use genetic manipulation to add CARs to T cells so they become highly efficient cancer-weapons. The receptor system incorporates signaling regions derived from T cells receptors that link with external fragment variable-single chain (scFv) linked antibody domains. Through this development T cells gain the ability to recognize tumors without needing human leucocyte antigen expression. The therapeutic approach using CAR-T cells achieves outstanding success by treating lymphoid cancer types including leukemia and lymphoma. CAR-T cells therapy represents an innovative cancer treatment method that uses immune system powers to find and destroy cancer cells. Clinical studies demonstrate that CAR-T cells generate extended disease control in patients who have B cell cancers while maintaining low sustained toxicity profiles and can potentially cure certain subgroups of patients. The medicine NexCAR19 represents India's inaugural CAR T-cell therapy system that marks a groundbreaking step forward for treating leukemia patients. The CDSCO granted approval to CAR-T cells therapy following development by Immuno ACT which operates as a startup incubated at IITB but this effective treatment comes with CRS and neurological side effects. Ongoing medical research works to enhance treatment procedures and study CAR design improvements alongside identification of resistance factors.

Introduction

Precise medicine and individualized cancer therapy take shape through the groundbreaking CAR T cells treatment methodology [1]. The breakthrough therapy demonstrates remarkable potential for transformative disease treatment within the field of oncology as a dynamic active solution. Multiple CAR-T cell products operate within a complex therapeutic framework which delivers distinct antigen recognition capabilities and brings remarkable clinical outcomes and FDA regulatory accreditations [2,3]. Cancer patients utilize CAR-T cells as custom-made fusion proteins that steer T cells to recognize specified tumor cell antigens thus triggering immune responses targeting the malignancy [4]. The cells used for CAR-T therapy often come from patients themselves (autologous) but sometimes they derive from different genetic backgrounds of donor cells (allogeneic) [5]. A specific laboratory process modifies T cells to create genetically modified receptors known as CAR proteins. After customizing or adjusting the lymphocytes' ability to recognize a specific antigen, they are cultured to increase in number and reintroduced into the patient's body. Once inside, they carry out their cytotoxic functions, aiding in the development of a prolonged immune response against the target. The modular nature of CAR-T cells therapies offers unprecedented flexibility in adjusting effector cell properties, allowing for customization of affinity, persistence, and potency. The complex structure of CARs, consisting of ligand-binding domains, spacer ectodomains, transmembrane domains, and cytoplasmic domains, facilitates precise antigen recognition and subsequent T-cell activation. Notably, the ligand-binding domain is crucial for antigen binding, while costimulatory domains enhance lymphocytic activity and memory formation, illustrating the sophistication of CAR-T cells therapy [8]. Advancements in CAR-T cells generations, from initial constructs to experimental fourth- and fifth-generation designs, underscore ongoing efforts to enhance therapeutic outcomes by improving effector capabilities and persistence. The incorporation of costimulatory domains in second and third-generation CARs has significantly enhanced lymphocytic activity and tenacity, laying the groundwork for further progress in the field. Additionally, the exploration of experimental fourth- and fifth-generation CARs, integrating novel transgenic signaling approaches, shows promise in enhancing therapeutic effectiveness and reducing toxicity [6]. Although there have been significant advancements, cytokine-release syndrome (CRS) and on-target off-tumor toxicity are still concerns that require ongoing research to ensure safety and effectiveness. The future of CAR-T cells therapy involves improving manufacturing processes, exploring innovative constructs, and developing approaches that minimize negative impacts while maximizing therapeutic gains. CAR-T cells therapy has revolutionized the field of oncology, offering a promising approach to treating various hematologic malignancies [7]. This article delves into the current landscape of CAR-T cells therapy, highlighting its successes, limitations, and ongoing strategies to enhance its efficacy and safety.

Manufacturing and Production Process of CAR-T cells Therapy

Manufacturing starts by collecting T-cells through peripheral blood isolation (figure:1). Blood samples draw through leukapheresis enable scientists to separate T-cells from remaining blood parts including red blood cells and plasma. T-cells function as the backbone of CAR-T therapy since researchers modify their genetic profile to encode tumor-specific chimeric antigen receptors (CARs) [8]. Scientists recover isolated T-cells from patient blood for genetic modification that creates CARs targeted against tumor antigens. CAR construct contains component domains that begin with an antigen-binding extracellular segment (formed from a monoclonal antibody single-chain variable fragment) and two sets of signaling domains and costimulatory domains CD28 or 4-1BB) which activate T-cells after antigen detection [9]. T-cells acquire CAR genes most frequently through the process of viral vector transduction. T-cell genetic material delivery efficiency represents one reason retroviral vectors including gamma-retroviral and lentiviral vectors are preferred for clinical applications. Viral vectors encode CAR transgene information to insert into T-cell genomes during transduction with the result being long-term CAR expression. After genetic modification occurs CAR-T cells receive laboratory conditions that allow cell number multiplication until therapeutic levels are reached. Cultured T-cells acquire sustained expression of CAR during their growth

period that involves regular application of cytokines including interleukin-2 or interleukin-7 and anti-CD3 antibody-stimulated culture. The expansion process targets the production of numerous CAR-T cells necessary for subsequent patient treatment. The manufacturing process of CAR-T cell products requires multiple quality control inspections which ensure safety alongside treatment effectiveness. The manufactured cells undergo multiple assessments to evaluate viability and examine cellular characteristics, CAR receptor activity and the absence of contaminants. CAR-T cells products move to storage and distribution after expansion and suitable characterization. The preservation method of cryogenic freezing protects cellular integrity which enables off-the-shelf tumor cell receptor therapies [10].



Figure 1: Schematic representation of the T-cell manufacturing process, starting with the isolation of T-cells from the patient's peripheral blood.

Design of cars t cells

The structure of CAR T cells functions as an essential component in cancer therapeutic processes. T cells receive their enhanced antigen recognition capability specifically for targeted activation from synthetic receptors known as CARs. The composition of CAR-T cells receptors incorporates a standard arrangement of four critical elements [11].

Antigen-Binding Domain

The CAR specific antigen-binding domain exists on the area that faces outside of the cell. The target antigen recognition by this region leads to lymphocytes' redirected specificity. Traditional CAR structures contain variable heavy (VH) chains along with variable light (VL) chains which combine to form single-chain variable fragment (scFv).Periodic (Gly4Ser)3 peptide linkers enable proper folding and antigen recognition performance [12].directing lymphocytes' specificity.

Traditionally composed of variable heavy (VH) and variable light (VL) chains of monoclonal antibodies, forming a single-chain variable fragment (scFv).

Utilizes flexible linkers like (Gly4Ser)3 peptide for proper folding and antigen recognition [12].

Hinge

Provides flexibility in the extracellular portion, aiding in antigen binding.

Determines the length and reach of the CAR for optimal binding.

Influences antigen access and signalling through the CAR.

Transmembrane Domain

Connects the extracellular domain to the intracellular signaling components.

Anchors the CAR in the T cells membrane.

Derived from proteins like CD3, CD28, CD4, or CD8α.

Intracellular Signaling Domain

Contains activation and co-stimulatory domains.

Activation domain typically derived from CD3ζ chain for initial signaling.

Co-stimulatory domains like CD28 or 4-1BB enhance T-cell function, metabolism, and persistence [13]

Mechanism of action

CAR-T functions through an elaborated technique enabling engineered T cells to discern and destroy cancer cells with precision. Following genetic modification of T lymphocytes into CAR-T cells physicians outfit the cells with CARs to detect cancer antigens. CAR-T cells identify their target antigen leading them to trigger multiple molecular processes that result in cancer cell elimination.

Antigen Recognition: Engineering CAR-T cells with recognition proteins called CARs gives them the capacity to detect distinct antigens present on cancer cells. The CAR cellular structureincludes a ligand-specific recognition domain built from antibody-like components along with signaling domain components extracted from the T cells receptor from normal cells. Stem cells engineered to carry CAR-encoded T cells receive their genetic modifications specifically for cancer cell target and elimination [14].

Formation of Immune Synapse: Upon recognition of the target antigen, a non-classical immune synapse is

formed between the CAR-Tcell and the cancer cell. This synapse facilitates multiple receptor-ligand interactions nearby, leading to the activation of the CAR-Tcell and the initiation of cytotoxic activity.

Cytotoxic Effects: CAR-T cellular activity kills targets in two main destructive pathways. Slow-Acting Killing Mechanisms: Through receptor-targeted TNF ligand signaling CAR-T cells can trigger apoptosis in cancer cells to initiate cell death. Perforin and granzyme granules released by CAR-T cells quickly form membrane pores in cancer cells until cell death occurs through both caspase-dependent and independent apoptotic pathways [15].

Cytokine Secretion: When activated CAR-T cells produce cytokines including IL-2, IL-6, and IFN-γ these immune-stimulating factors actively attract and strengthen natural killer (NK) cells and macrophages while recruiting further T cells into the tumor environment. When cells collaborate with each other in the immune response it generates enhanced protection against tumor cells which contributes to cancer cell destruction [16**].**



Figure 2: Mechanism of CAR-T Cell Therapy.

Different generations of car-t cells

The different generations of CAR-T cells are classified based on the structure of their CARs which have evolved to enhance their therapeutic efficacy.

First-generation CAR-T cells

Structure: Composed of an extracellular antigen-recognition domain linked to a single intracellular motif encoding the CD3 cytoplasmic T cells glycoprotein.

Function: Triggered cellular response against target antigens but displayed limited persistence and clinical benefits(figure:2).

Limitation: Showed limited efficacy due to inadequate signaling for a robust T-cell response.

Second-generation CAR-T cells

Structure: An additional signaling motif obtained from CD28 and 4-1BB/CD137 costimulatory receptors was integrated into the CD3-activating domain.

Function: Enhanced effector functions and increased persistence compared to first-generation CAR-T cells.

Third-generation CAR-T cells

Structure: Included a second costimulatory signaling domain, often combining CD28 with 4-1BB, to further improve antitumor abilities.

Advantages: Improved persistence, proliferation, cytotoxicity, cytokine release, and memory formation.

Fourth- and Fifth-generation CAR-T cells

Structure: Research demands the combination of constitutive along with inducible transgenic signal pathways which includes both cytokines (TRUCKs) and chemokines (self-driving CARs).

Function: These experimental generations aim to optimize the design of CAR-T cells for improved safety, efficacy, and persistence in treating various cancers.

The evolution of CAR-T cell generations, as shown in figure:3, is driven by the need to address challenges such as immune-mediated toxicities, limited persistence, and the immunosuppressive tumor microenvironment. Each generation builds upon the previous one by incorporating advancements in structure and signaling domains to enhance the overall effectiveness of CAR-T cell therapy [17].



Figure3:Evolution of CAR-T cell generations, highlighting the advancements made to address challenges such as immune-mediated toxicities, limited persistence, and the immunosuppressive tumor microenvironment.

The therapeutic use of CAR-T cell technology proves extremely effective at treating blood cancer diseases starting from B-cell malignancies. The novel immunotherapy achieves remarkable response results in patients with diseases including B cell relapsed or refractory leukemia, lymphoma, and multiple myeloma. This therapeutic approach produces stable disease remission that represents important advancements in cancer management [18].

Efficacy

The use of CAR-T cells therapy demonstrates exceptional outcomes among different disease groups resulting in prolonged disease elimination. Therapy received FDA approval to treat acute lymphoblastic leukemia (ALL) and large B cell lymphoma (LBCL) as well as follicular lymphoma (FL) and mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) and multiple myeloma (MM).Ongoing investigations focus on creating better CAR-T cell therapy systems while developing new toxicology-targeted strategies to improve CAR-T cell treatment effectiveness although research faces challenges regarding off-target tumor selectivity and CAR-T cell failures and immunologic escape.lar lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and multiple myeloma (MM).

Despite certain limitations like on-target/off-tumor targeting, antigen escape, and CAR-T cells dysfunction, ongoing research aims to enhance the efficacy of CAR-T cells therapy by developing novel toxicity-directed therapies and toxicity-limited constructs.

Toxicities

The side effects of CAR-T cell treatment include both CRS (cytokine release syndrome) and ICANS (immune effector cell-associated neurotoxicity syndrome). The symptoms of CRS appear at various clinical severity levels yet doctors can control both CRS and life-threatening manifestations through tocilizumab and steroid prescriptions.

ICANS combined with CRS produces neurological symptoms that include encephalopathy with seizures along with obtundation. Two main therapy approaches for toxicities include supportive treatments combined with CRS intervention by tocilizumab followed by neurotoxicity management using steroid medications. and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS can range from mild to life-threatening symptoms and is managed with tocilizumab and steroids.

ICANS can lead to neurological symptoms like encephalopathy, seizures, and obtundation, often observed alongside CRS.

Toxicity-directed therapies involve supportive care, tocilizumab for CRS, and steroids for neurotoxicity. Research continues for additional agents such as siltuximab and etanercept and infliximab and anakinra together with lenzilumab for toxicity management.

Ongoing research in car-Tcell therapy

Current status

The clinical success of adoptive CAR-T cells transfer has drawn significant attention because studies show durable responses including total tumor clearance and disease remission (Table:1). Each patient treated through CAR-T cells therapy in B cell acute lymphoblastic leukemia (B-ALL) demonstrated complete disease elimination along with negative minimal residual disease (MRD-). Anti-CD19 CAR-T cells treatment within clinical settings yielded complete remission in eight patients yet partial remission in four patients who had advanced B cell malignancies. CAR-T cells achieved regulatory approval by showing both

rapid and persistent action in patients with B-ALL who had relapsed or refractory disease stages through high remission rates. Protein expression-blocking methods minimize CAR-T cells destructive behavior toward T cells acute lymphoblastic leukemia cells in vivo. The approved CAR-T therapy medications Yescarta, Kymriah alongside Breyanzi and Tecartus present survival rates which vary from 65% at 12 months to 42.6 at five-year evaluation [19].

Challenges:

Allogeneic CAR-T cells: The current standard utilizes autologous CAR-T cells, derived from the patient themselves. Research is actively pursuing the development of "off-the-shelf" allogeneic CAR-T cells from healthy donors. This would improve accessibility, reduce manufacturing time, and potentially benefit a wider patient population.

Solid Tumor Targeting: Most approved CAR-T therapies effectively target hematological malignancies (blood cancers). Significant research effort is directed toward designing CAR-T cells that can efficiently target and eliminate solid tumors, presenting a more complex challenge due to the tumor microenvironment.

Side Effect Management: Cytokine release syndrome (CRS) and CAR T-cell related encephalopathy (CAR T-CRE) are potential side effects of CAR-T cells therapy. Researchers are developing strategies to effectively manage these adverse events and enhance patient safety [20].

Expanding Treatment Applications

Targeting Novel Antigens: Identifying and characterizing new cancer-specific cell surface antigens is crucial for expanding the scope of CAR-T cells therapy to a broader spectrum of malignancies.

Combination Therapies: Clinical trials are investigating the synergistic effects of combining CAR-T cells therapy with established cancer treatments like chemotherapy or radiation therapy, potentially leading to improved clinical outcomes.

Advancements in CAR-T cells Engineering

"Dual-Targeted" CAR-T cells: Novel CAR designs are being developed to target two distinct antigens on cancer cells simultaneously. This approach aims to overcome tumor escape mechanisms and potentially enhance therapeutic efficacy.

Universal CAR-T cells: Research is exploring the creation of CAR-T cells capable of targeting multiple cancer types. This development holds promise for a more versatile treatment approach with broader applicability [21].

Table 1: FDA-approved CAR T-cell Therapies

Brand Name	Generic Name	Target Antigen	Acceptable Dose
ABECMA	Idecabtagene vicleucel [**22**]	CD19	Adult patients with relapsed or refractory multiple myeloma.
BREYANZI	Lisocabtagene maraleucel [**23**]	CD19	Adult patients with apsed or refractory large B-cell lymphoma
CARVYKTI	Ciltacabtagene autoleucel [**24**]	BCMA	Patients with relapsed/refractory multiple myeloma.
KYMRIAH	Tisagenlecleucel [**25**]	CD19	ituximab treats patients who have DLBCL after atment failure or relapse ong with younger adults who have refractory or apsed ALL up to age 25.
TECARTUS	Brexucabtagene autoleucel [**26**]	CD19	atients with relapsed or refractory mantle cell lymphoma and adult atients with relapsed or fractory B-cell precursor acute lymphoblastic leukemia (ALL).
YESCARTA	Axicabtagene ciloleucel [**27**]	CD19	DLBCL patients who failed two or more evious treatment options, whose condition did not show improvement.

Limitations

The revolutionary power of CAR-T cells treatment in cancer therapy is undermined because of multiple constraints which diminish its treatment effectiveness. Acute toxicities that threaten patients' lives together with insufficient tumor response and inhibition of target antigens and impaired cell movement and insufficient tissue penetration and modulations of the immune environment limit CAR-T cells effectiveness [28]. The loss or decreased expression of target antigens by tumor cells results in patient relapse through antigen escape resistance to single antigen-targeting CAR constructs. The clinical testing of dual or tandem CARs targeting multiple antigens demonstrates promising treatment efficiency for overcoming this challenge. The implementation of CAR-T cell therapies faces hurdles involving

activation against off-target cells and cancer sites in addition to problems with cell distribution and the suppressive nature of tumor environments and adverse reactions from treatment. The development of local administration methods and checkpoint blockade treatment together with enhanced chemokine receptor expression and specialized CAR-T cell penetration technologies represent strategic approaches to tackle these therapy challenges. The occurrence and severity of CRS and HLH/MAS and ICANS become more likely due to CAR design characteristics and tumor type selection as well as target-specificities during CAR-T therapy. The CAR structure's antigen-binding domain affinity and hinge-region and transmembrane domain modifications alongside costimulatory domain adjustments based on different factors help reduce toxicity while enhancing therapeutic results [29].

Current challenges

Low CAR-T cells persistence, antigen escape events, insufficient tumor-killing efficacy, and high toxicity profiles are challenges that plague approved treatments and hinder the development of novel therapies. The prolonged manufacturing period and high costs of currently available products are additional challenges in CAR-T cells therapy**.** Lymphodepleting conditioning, a type of chemotherapy, is used before CAR-T cells infusion to enhance CAR-Tcell expansion and persistence post-infusion**.** Bridging therapy, consisting of immunotherapy, chemo- or radiotherapy, is often required to keep disease progression at bay while patients wait for CAR-Tcell therapy. Other safety concerns include anaphylaxis, graft-versus-host disease, off-target toxicity, and potential viral insertional oncogenesis **[30].**

Future direction for research and clinical trial

Advancements in synthetic biology and cell engineering offer promising avenues for the development of novel therapies, particularly in the optimization of CAR T-cell therapy for cancer treatment. While these innovations enhance efficacy, they also raise concerns regarding increased complexity and associated risks, such as off-target gene disruption and potential malignant transformation of T-cells. Recent strategies involve precise gene editing, like inserting CAR genes into specific loci or employing CRISPR-Cas9 to eliminate undesirable genetic elements. Despite initial successes, challenges persist, including long-term risk assessment, manufacturing costs, and scalability. Ongoing monitoring of gene-editing-related complications in clinical trials is crucial for identifying and addressing potential issues[31]. Efforts to mitigate costs include exploring alternative vector systems and streamlining manufacturing processes. However, the expense remains a significant consideration, particularly concerning the development of clinical-grade retroviruses. Despite these challenges, continued advancements in gene editing hold promise for improving CAR T-cell therapy and expanding its accessibility in anti-cancer treatment[31].

India’s pioneering contribution to car-tcell therapy

The Indian medical industry has produced native CAR-T cells therapeutic solutions which can be referred to as NexCAR19. Drug regulator approval granted to India for NexCAR19 treatment of leukemia and lymphoma B-cell cancers came from Mumbai-based Immuno ACT in partnership with the Indian Institute of Technology Bombay along with Tata Memorial Centre. With NexCAR19 researchers reengineer patient immune cells through laboratory protocols to deliver a chimeric antigen receptor which enables modified T cells to recognize cancer cells. CAR-T cells therapy research breakthrough demonstrates both cost-effective treatment potential and Indian medical research capabilities for creating innovative healthcare technologies appropriate for local usage [32].

Conclusion

This therapy progresses, discussions concerning its accessibility, effectiveness, and potential side effects are pivotal for both patients and healthcare providers. Patients who have undergone CAR-Tcell therapy often share their firsthand experiences, such as individuals who received this treatment as their primary therapy after induction therapy. These personal narratives offer valuable insights into the real-world impact of CAR-T cell therapy on patients' lives and treatment outcomes. CAR T-cell therapy, a remarkable achievement in bioengineering innovation, has revolutionized the landscape of medical oncology and beyond by offering unprecedented treatment prospects. As our

understanding deepens and technology advances, its application to solid malignancies is inevitable. Despite lingering challenges such as CAR T-cell refractory disease and safety concerns, ongoing advancements in construct modifications and strategic refinements ensure a dynamic progression in research. This relentless pursuit of innovation promises to propel these therapies to new frontiers, fostering remarkable breakthroughs in the future.

Acknowledgement

The author's expresses his gratitude toward Hon. Chancellor, Prof. Syed Waseem Akhtar, Integral University and Vice-Chancellor, Prof. Javed Musarrat, Integral University for providing research environment and all necessary facility for conducting research. Author's also want expresses his gratitude toward Prof. (Dr.). Amita Verma Sam Higginbottom University of Agriculture, Prayagraj Uttar Pradesh 211007, India.

Ethical approval

NA

Informed consent

Not Applicable.

Funding

No funding was received for conducting this study.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare no conflict of interest among themselves. The authors alone are responsible for the content and writing of this article.

Financial interests

The authors declare they have no financial interests.

References

1. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T. Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma. Journal of clinical oncology. 2015 May 20;33(15):1688-96.

2. Ahmad A. CAR-T cell therapy. International Journal of Molecular Sciences. 2020 Jun 17;21(12):4303.

3. Almåsbak H, Aarvak T, Vemuri MC. CAR T cell therapy: a game changer in cancer treatment. Journal of immunology research. 2016;2016(1):5474602.

4. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Molecular Therapy-Oncolytics. 2016 Jan 1;3.

5. Coschi CH, Ishak CA, Gallo D, Marshall A, Talluri S, Wang J, Cecchini MJ, Martens AL, Percy V, Welch I, Boutros PC. Haploinsufficiency of an RB–E2F1–Condensin II complex leads to aberrant replication and aneuploidy. Cancer discovery. 2014 Jul 1;4(7):840-53.

6. Earle WR, Crisp LR. Production of malignancy in vitro. Journal of the National Cancer Institute: JNCI.. 1943;4:135.

7. El Warrak S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, Chavez J, Mohty R. Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy. Bone Marrow Transplantation. 2024 Feb;59(2):162-70.

8. Hamadani M, Lucero M, DeVos JD, Chen L. Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine. eJHaem.

9. Han Z, Ma X, Ma G. Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications. Heliyon. 2024 Mar 16.

10. Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer cell. 2020 Oct 12;38(4):473-88.

11. Huang Q, Li H, Zhang Y. A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023. Human Vaccines & Immunotherapeutics. 2024 Dec 31;20(1):2371664.

12. Jia Y. Applications, Efficacies, Potential Side Effects, and Expectations of CAR-T Cell Therapy in the Treatment of Acute Lymphoblastic Leukemia. Highlights in Science, Engineering and Technology. 2023 Dec 29;74:187-93.

13. Kanate AS, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, Herrera AF, Inamoto Y, Jain T, Perales MA, Carpenter PA. Updated indications for immune effector cell therapy: 2023 guidelines from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy. 2023 Oct 1;29(10):594-7.

14. Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Molecular therapy Methods & clinical development. 2017 Mar 17;4:92-101.

15. Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in universal CAR-T cell therapy. Frontiers in immunology. 2021 Oct 6;12:744823.

16. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD. Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine. 2014 Oct 16;371(16):1507-17.

17. Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: A new era for cancer treatment. Oncology reports. 2019 Dec 1;42(6):2183-95.

18. Newick K, O'Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annual review of medicine. 2017 Jan 14;68(1):139-52.

19. Penn I. Malignancy. Surgical Clinics of North America. 1994 Oct 1;74(5):1247-57.

20. Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J. CD19-directed CART therapy for T cell/histiocyte rich large B-cell lymphoma. Blood Advances. 2024 Jul 10:bloodadvances-2024013863.

21. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature reviews Clinical oncology. 2020 Mar;17(3):147-67.

22. Sahlolbei M, Ahmadieh-Yazdi A, Rostamipoor M, Manoochehri H, Mahaki H, Tanzadehpanah H, Kalhor N, Sheykhhasan M. CAR T-Cell Therapy: A New Era in Cancer Immunotherapy.

23. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nature reviews Clinical oncology. 2019 Jun;16(6):372-85.

24. Siu KS, Zheng X, Liu Y, Zhang Y, Zhang X, Chen D, Yuan K, Gillies ER, Koropatnick J, Min WP. Single-walled carbon nanotubes noncovalently functionalized with lipid modified polyethylenimine for siRNA delivery in vitro and in vivo. Bioconjugate chemistry. 2014 Oct 15;25(10):1744-51.

25. Srivastava S, Riddell SR. Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. The Journal of Immunology. 2018 Jan 15;200(2):459-68.

26. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal. 2021 Apr 6;11(4):69.

27. Sugiyama K, Amano Y. Morphological and biological properties of a new coronavirus associated with diarrhea in infant mice. Archives of virology. 1981 Sep;67:241-51.

28. Szymanek-Pasternak A, Marchewka Z, Szymańska B, Filipowski H, Zalewska M, Knysz B. Assessment of the usefulness of β2-microglobulin and retinol binding protein for the purpose of testing kidney function in HIV-positive patients. HIV & AIDS Review. 2014 Jan 1;13(2):40-5.

29. Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. Journal of hematology & oncology. 2017 Dec;10:1-1.

30. Zhang C, Liu J, Zhong JF, Zhang X. Engineering car-t cells. Biomarker research. 2017 Dec;5:1-6.

31. Arabi F, Mansouri V, Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview. Biomedicine & Pharmacotherapy. 2022 Sep 1;153:113324.

32. Menon T, Gopal S, Rastogi Verma S. Targeted therapies in non-small cell lung cancer and the potential role of AI interventions in cancer treatment. Biotechnology and Applied Biochemistry. 2023 Feb;70(1):344-56.